Post-inflammatory hyperpigmentation (PIH): causes, treatment, and why darker skin tones need a different approach

Post-inflammatory hyperpigmentation (PIH) is the dark spot or patch of discoloration left behind after skin inflammation — a wound healing response where melanocytes produce excess melanin. It affects all skin tones but is disproportionately severe and persistent in Fitzpatrick IV–VI skin. Here's the pathophysiology, evidence-based treatment, and why the approach must differ by skin tone.

What causes PIH

The melanogenesis response to inflammation

Any inflammatory event — acne, eczema flare, insect bite, allergic reaction, wound, cosmetic procedure, or even aggressive skincare — triggers a cytokine cascade:

Inflammatory mediators (prostaglandins, leukotrienes, thromboxanes, interleukins) are released from keratinocytes and immune cells
These mediators stimulate melanocytes in the basal epidermis to produce excess melanin
Melanosomes (melanin granules) are transferred to surrounding keratinocytes
Melanin deposits accumulate → visible hyperpigmentation

The key insight: the inflammation itself causes the melanin overproduction. The underlying trigger (acne, eczema) is only the first step; the inflammatory response is the PIH-generating event. This is why preventing inflammation is as important as treating existing PIH.

Epidermal vs. dermal PIH

Type	Location	Appearance	Prognosis
Epidermal	Epidermis	Brown; enhances under Wood's lamp	Responds well to topicals; fades over months
Dermal	Dermis	Gray-blue or purple-brown; no Wood's lamp enhancement	Difficult; requires professional treatment
Mixed	Both	Variable	Variable

Dermal PIH (melanin in melanophages in the upper dermis) occurs when epidermal PIH is so severe that melanin drops below the dermal-epidermal junction. It is the hardest to treat and the most prone to permanent persistence.

Fitzpatrick skin tone and PIH risk

PIH severity and persistence correlate strongly with skin phototype:

Fitzpatrick Type	Baseline melanin	PIH severity	Laser/chemical peel PIH risk
I–II (very fair)	Low	Mild; fades in weeks–months	Low
III–IV (light-medium brown)	Moderate	Moderate; months to 1–2 years	Moderate
V–VI (brown–dark brown)	High	Severe; can be years to permanent	High if protocol not Fitzpatrick-appropriate

Mechanism: Higher baseline melanocyte activity in darker skin tones means a proportionally larger inflammatory response produces a proportionally larger melanin output. The same acne lesion leaves a faint mark in Fitzpatrick II skin and a dark persistent patch in Fitzpatrick VI skin.

This is not cosmetic preference — it is a biological difference that changes which treatments are appropriate and which are unsafe.

Evidence-based topical treatments

The topical pigmentation treatment stack

Effective PIH treatment targets multiple points in the melanogenesis pathway simultaneously:

Tyrosinase inhibitors (reduce melanin synthesis)

Tranexamic acid (2–5%): Inhibits plasmin-mediated prostaglandin production → reduces upstream melanocyte stimulation. Ebrahimi & Malaekeh-Nikouei 2014 (IJDVL): 3% TXA comparable to 3% HQ for melasma; excellent extrapolation to PIH. Safe across all Fitzpatrick types.
Alpha-arbutin (1–2%): Inhibits tyrosinase with less irritation risk than hydroquinone; no ochronosis risk; safe in pregnancy.
Azelaic acid (10–20%): Selectively targets hyperactive melanocytes; anti-inflammatory (dual benefit — reduces both the melanin production and the inflammatory driver of PIH); FDA-approved; safe in Fitzpatrick IV–VI.
Kojic acid (1–2%): Copper chelation → tyrosinase inhibition; less stable but effective; can cause contact sensitization with prolonged use.
Hydroquinone (2–4%): Gold standard tyrosinase inhibitor; most evidence for pigmentation; 4% Rx most effective; ochronosis risk with long-term use (>6 months); cycle off every 3–4 months.

Melanin transfer inhibitors

Niacinamide (5–10%): Inhibits melanosome transfer from melanocytes to keratinocytes; reduces visible pigmentation without affecting melanin synthesis; Hakozaki et al. 2002 (BJD): 5% niacinamide significantly reduced hyperpigmentation vs. vehicle at 8 weeks.

Cell turnover (accelerate pigmented cell shedding)

Retinoids (retinol, adapalene, tretinoin): Accelerate epidermal turnover → faster clearance of melanin-laden keratinocytes; increase HA and collagen production; tretinoin most potent. Caution: retinoid dermatitis (dryness, redness) can worsen PIH if not managed.
AHAs (glycolic 5–10%, lactic 5–10%): Loosen desmosomal bonds between keratinocytes; accelerate pigmented cell shedding. Start at low concentrations in Fitzpatrick IV–VI to avoid irritation-induced PIH worsening.

Optimal combination approach

Tranexamic acid + alpha-arbutin + niacinamide + AHA → covers upstream melanocyte stimulation, synthesis, transfer, and cell turnover simultaneously. This non-HQ combination is preferred when HQ is not being used (or during HQ cycling-off periods).

Professional treatments

Chemical peels

Fitzpatrick I–III:

Glycolic acid 20–70%: series of 4–6 peels; 2–4 week intervals
Jessner's peel: combination lactic acid + salicylic acid + resorcinol; well-tolerated

Fitzpatrick IV–VI (critical safety principles):

Start with lactic acid 30–50% (gentler than glycolic; lower PIH risk)
Mandelic acid 20–30%: Larger molecule → slower, more even penetration; specifically studied in darker skin
Avoid TCA >15% in Fitzpatrick V–VI — very high PIH risk
Pre-condition with topical tyrosinase inhibitors for 4–6 weeks before any peel to reduce PIH risk

Laser and light (skin of color safety is critical)

For Fitzpatrick I–III:

IPL (540–690 nm): targets melanin; effective for superficial PIH
Q-switched Nd:YAG 532 nm: effective for epidermal PIH
Fractional lasers: resurfacing with some PIH risk; manageable in I–III

For Fitzpatrick IV–VI (requires Fitzpatrick-appropriate protocols):

Q-switched Nd:YAG 1064 nm (low-fluence toning): Low-energy multi-session approach; better safety in darker skin than high-fluence settings or 532 nm
Picosecond lasers (1064 nm): Faster pulse → photomechanical effect vs. thermal → lower PIH risk in darker skin; growing evidence base
Fractional non-ablative (1540, 1927 nm): Can be used cautiously in darker skin by experienced providers; aggressive settings cause PIH
Avoid: IPL, ablative CO2/erbium, Q-switched 532 nm — all carry very high PIH risk in Fitzpatrick V–VI

Rule: Never receive laser treatment for PIH in Fitzpatrick IV–VI skin from a provider without documented experience treating skin of color. Iatrogenic PIH from laser is common, can be severe, and is very difficult to treat.

The prevention principle: stopping PIH at the source

Because PIH is an inflammatory response, preventing the inflammation prevents the PIH:

Treat acne promptly: Each unresolved acne lesion is a PIH factory. Starting effective acne treatment early reduces the total inflammatory burden and future PIH
Don't pick or squeeze: Mechanical trauma intensifies the inflammatory response → deeper and darker PIH
Manage eczema flares early: Each flare in Fitzpatrick IV–VI skin risks dermal PIH
Daily SPF 50+: UV worsens existing PIH through melanocyte stimulation and slows fading; use broad-spectrum SPF every day (not just on sunny days)
Mineral SPF in Fitzpatrick V–VI: Iron oxides in tinted mineral sunscreens block visible light — which can also stimulate melanin in darker skin where visible light is a meaningful trigger

Timeline expectations

Fitzpatrick Type	Mild PIH (shallow, epidermal)	Moderate PIH	Severe/Dermal PIH
I–II	4–8 weeks with topicals	2–4 months	6+ months; may need professional treatment
III–IV	3–6 months with topicals	6–12 months	1–2 years; professional treatment usually needed
V–VI	6–12 months with topicals	1–2+ years	May be permanent without professional treatment

The most important variable: Consistent daily SPF. PIH that is not protected from UV takes 3–5× longer to fade regardless of topical treatment efficacy.

Looking for a PIH or hyperpigmentation consultation? Browse skincare providers on MedSpot →